Please ensure Javascript is enabled for purposes of website accessibility

Why ChemoCentryx Stock Is Cratering Again Today

By Keith Speights - May 7, 2021 at 12:22PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors aren't optimistic after an FDA advisory committee vote for avacopan.

What happened

Shares of ChemoCentryx (CCXI -0.53%) were cratering by 58.3% as of 11:40 a.m. EDT on Friday. The stock also crashed on Tuesday after the U.S. Food and Drug Administration (FDA) released briefing documents for an advisory committee that expressed significant reservations about the company's data for avacopan. Today's huge decline came after that advisory committee's vote on recommending approval for the experimental therapy.

So what

Based on the performance of the biotech stock today, you might have expected that the advisory committee overwhelmingly voted against recommending approval for avacopan. That wasn't the case, though. The committee voted 10-to-8 in favor of approval of the drug in treating anti-neutrophilic cytoplasmic autoantibody (ANCA)-vasculitis, a rare disease that causes small blood vessels to swell. 

One thumb up and another thumb down

Image source: Getty Images.

There were actually multiple votes by the advisory committee. On the question of whether the efficacy data from ChemoCentryx's clinical study supported approval, there was a tie with nine members voting for and nine voting against. The committee also voted 10-to-8 that the safety profile of avacopan was sufficient to support FDA approval.

The FDA doesn't have to follow the recommendation of the advisory committee. Although the agency usually does go along with committee recommendations, it's clear that investors don't expect that to happen this time.

Now what

ChemoCentryx's hopes for avacopan now rest with the FDA. If the agency doesn't approve the drug, it's likely that the company will have to conduct another clinical study before it can refile for approval.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ChemoCentryx, Inc. Stock Quote
ChemoCentryx, Inc.
$50.60 (-0.53%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.